Search Results - "VAN GAAL, L"

Not performing an OGTT results in significant underdiagnosis of (pre)diabetes in a high risk adult Caucasian population by Meijnikman, A S, De Block, C E M, Dirinck, E, Verrijken, A, Mertens, I, Corthouts, B, Van Gaal, L F

“…Objective: Type 2 diabetes (T2DM) is known to be underdiagnosed. Tests for diagnosis include fasting plasma glucose (FPG), oral glucose tolerance test (OGTT)…”
Get full text

Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function by Hectors, T. L. M., Vanparys, C., van der Ven, K., Martens, G. A., Jorens, P. G., Van Gaal, L. F., Covaci, A., De Coen, W., Blust, R.

“…The prevalence of diabetes mellitus is currently at epidemic proportions and it is estimated that it will increase even further over the next decades. Although…”
Get full text

Screening for therapeutic trials and treatment indication in clinical practice: MACK‐3, a new blood test for the diagnosis of fibrotic NASH by Boursier, J., Anty, R., Vonghia, L., Moal, V., Vanwolleghem, T., Canivet, C. M., Michalak, S., Bonnafous, S., Michielsen, P., Oberti, F., Iannelli, A., Van Gaal, L., Patouraux, S., Blanchet, O., Verrijken, A., Gual, P., Rousselet, M.‐C., Driessen, A., Hunault, G., Bertrais, S., Tran, A., Calès, P., Francque, S.

“…Summary Background The composite histological endpoint comprising nonalcoholic steatohepatitis (NASH) and NAFLD activity score ≥4 and advanced fibrosis (F ≥ 2)…”
Get full text

LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial by Masmiquel, L, Leiter, L A, Vidal, J, Bain, S, Petrie, J, Franek, E, Raz, I, Comlekci, A, Jacob, S, van Gaal, L, Baeres, F M M, Marso, S P, Eriksson, M

“…Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk. We used the…”
Get full text

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects by WILDING, J, VAN GAAL, L, RISSANEN, A, VERCRUYSSE, F, FITCHET, M

“…Treatment of obese subjects with topiramate has recently been associated with significant weight loss in a 6-month dose-ranging study. To investigate the…”
Get full text

Obesity, haemostasis and the fibrinolytic system by Mertens, I., Gaal, L. F. Van

“…Summary Obese patients are at risk for the development of cardiovascular diseases, which can in part be explained by disturbances in the haemostatic and…”
Get full text

Visceral, subcutaneous abdominal adiposity and liver fat content distribution in normal glucose tolerance, impaired fasting glucose and/or impaired glucose tolerance by Borel, A-L, Nazare, J-A, Smith, J, Aschner, P, Barter, P, Van Gaal, L, Eng Tan, C, Wittchen, H-U, Matsuzawa, Y, Kadowaki, T, Ross, R, Brulle-Wohlhueter, C, Alméras, N, Haffner, S M, Balkau, B, Després, J-P

“…Objectives: To examine the specific distribution of liver fat content, visceral and subcutaneous adiposity in normal glucose tolerance (NGT/NGT), isolated…”
Get full text

Pivotal Role for the Visceral Fat Compartment in the Release of Persistent Organic Pollutants During Weight Loss by Dirinck, E, Dirtu, A. C, Jorens, P. G, Malarvannan, G, Covaci, A, Van Gaal, L. F

“…Context: Polychlorinated biphenyls (PCBs), are implicated as potential endocrine disruptors and obesogens. These lipophilic substances are preferentially…”
Get full text

Assessing the impact of complications on the costs of Type II diabetes by WILLIAMS, R, VAN GAAL, L, LUCIONI, C

“…'The Cost of Diabetes in Europe - Type II (CODE-2) study' provides the first coordinated attempt to assess the total costs of managing people with Type II…”
Get full text

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials by Davidson, J. A., Desouza, C., Fonseca, V., Frias, J. P., Van Gaal, L., Giorgino, F., Chao, J., Dex, T. A., Roberts, M., Saremi, A., Leiter, L. A.

“…Aims Both fasting (FPG) and postprandial plasma glucose (PPG) contribute to HbA1c levels. We investigated the relationship between achievement of American…”
Get full text

Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease by Weyler, J., Verrijken, A., Hornemann, T., Vonghia, L., Dirinck, E., von Eckardstein, A., Vanwolleghem, T., Michielsen, P., Peiffer, F., Driessen, A., Hubens, G., Staels, B., Francque, S., Van Gaal, L.

“…Background Non-alcoholic fatty liver disease (NAFLD) is the most important cause of chronic liver disease in the western world. Steatosis can be accompanied by…”
Get full text

Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome by Mertens, I, Verrijken, A, Michiels, J.J, Planken, M. van der, Ruige, J.B, Gaal, L.F. van

“…Objective: To investigate whether leukocyte count, fibrinogen, von Willebrand factor (vWF) and plasminogen activator inhibitor-1 activity (PAI-1) are increased…”
Get full text

Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension by Francque, S, Verrijken, A, Mertens, I, Hubens, G, Marck, E. van, Pelckmans, P, Michielsen, P, Gaal, L. van

“…Introduction: We previously demonstrated in an animal model that steatosis, in the absence of fibrosis, induces a significant rise in portal pressure,…”
Get full text

Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes by Andersson, C., van Gaal, L., Caterson, I. D., Weeke, P., James, W. P. T., Couthino, W., Finer, N., Sharma, A. M., Maggioni, A. P., Torp-Pedersen, C.

“…Aims/hypothesis The optimal HbA 1c concentration for prevention of macrovascular complications and deaths in obese cardiovascular high-risk patients with type…”
Get full text

Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients by Verrijken, A, Francque, S, Mertens, I, Talloen, M, Peiffer, F, Gaal, L. Van

“…Objective: To study the relationship between elevated liver tests and high sensitive C-reactive protein (hs-CRP), as potential markers of liver inflammation…”
Get full text

Mutation screen of the SIM1 gene in pediatric patients with early-onset obesity by Zegers, D, Beckers, S, Hendrickx, R, Van Camp, J K, de Craemer, V, Verrijken, A, Van Hoorenbeeck, K, Verhulst, S L, Rooman, R P, Desager, K N, Massa, G, Van Gaal, L F, Van Hul, W

“…Background: The transcription factor SIM1 (Single-minded 1) is involved in the control of food intake and in the pathogenesis of obesity. In mice, Sim1 is…”
Get full text

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial by Caterson, I. D., Finer, N., Coutinho, W., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Legler, U. F., Shepherd, G. M., Rode, R. A., Perdok, R. J., Renz, C. L., James, W. P. T.

“…Aim: The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced greater mean weight loss than placebo but increased cardiovascular…”
Get full text

Human leptin: from an adipocyte hormone to an endocrine mediator by Wauters, M, Considine, RV, Van Gaal, LF

“…Leptin is a mainly adipocyte-secreted protein that was discovered 5 years ago. Most of the research following this discovery focused on the role of leptin in…”
Get full text

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes by Wolffenbuttel, B. H. R., Van Gaal, L., Durán-Garcia, S., Han, J.

“…This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30–35…”
Get full text

Sleep-Disordered Breathing and the Metabolic Syndrome in Overweight and Obese Children and Adolescents by Verhulst, S.L., MD, Schrauwen, N, Haentjens, D., MD, Rooman, R.P., MD, PhD, Van Gaal, L., MD, PhD, De Backer, W.A., MD, PhD, Desager, K.N., MD, PhD

“…Objective To assess whether sleep-disordered breathing (SDB) is a risk factor of the metabolic syndrome (MS) in children and adolescents who are overweight and…”
Get full text